BioCryst [BCRX] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

BioCryst Pharmaceuticals Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: BioCryst Pharmaceuticals Inc. wins in 11 metrics, Haleon Plc - ADR wins in 9 metrics, with 0 ties. BioCryst Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric BioCryst Pharmaceuticals Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) 7.09 18.72 BioCryst Pharmaceuticals Inc.
Price-to-Book Ratio -15.53 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio -4.01 52.37 Haleon Plc - ADR
PEG Ratio -0.01 15.42 Haleon Plc - ADR
EV/EBITDA 6.71 33.08 BioCryst Pharmaceuticals Inc.
Profit Margin (TTM) 30.16% 15.11% BioCryst Pharmaceuticals Inc.
Operating Margin (TTM) 65.60% 23.17% BioCryst Pharmaceuticals Inc.
EBITDA Margin (TTM) 65.60% 23.17% BioCryst Pharmaceuticals Inc.
Return on Equity -221.45% 10.27% Haleon Plc - ADR
Return on Assets (TTM) 43.22% 4.67% BioCryst Pharmaceuticals Inc.
Free Cash Flow (TTM) $344.90M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return -16.10% -16.01% Haleon Plc - ADR
Price-to-Sales Ratio (TTM) 2.46 3.78 BioCryst Pharmaceuticals Inc.
Enterprise Value $2.35B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 2.69 8.23 BioCryst Pharmaceuticals Inc.
Gross Profit Margin (TTM) 97.66% 55.38% BioCryst Pharmaceuticals Inc.
Revenue per Share (TTM) $4 $2 BioCryst Pharmaceuticals Inc.
Earnings per Share (Diluted) $1.21 $0.50 BioCryst Pharmaceuticals Inc.
Beta (Stock Volatility) 0.69 0.33 Haleon Plc - ADR
Short % of Float 14.08% 0.43% Haleon Plc - ADR

BioCryst Pharmaceuticals Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

BCRX
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
BioCryst Pharmaceuticals Inc.4.14%7.47%0.44%-2.58%19.37%20.80%
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
BioCryst Pharmaceuticals Inc.-16.10%17.41%-45.25%210.71%117.50%-30.40%
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%

Performance & Financial Health Analysis: BioCryst Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricBCRXHLN
Market Information
Market Cap i$2.20B$42.40B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i4,555,2976,594,249
90 Day Avg. Volume i6,070,5627,985,230
Last Close$9.06$9.07
52 Week Range$6.00 - $10.47$8.65 - $11.28
% from 52W High-13.47%-19.59%
All-Time High$37.25 (Mar 06, 2000)$11.42 (Jun 02, 2025)
% from All-Time High-75.68%-20.58%
Growth Metrics
Quarterly Revenue Growth2.09%0.01%
Quarterly Earnings Growth2.09%0.86%
Financial Health
Profit Margin (TTM) i0.30%0.15%
Operating Margin (TTM) i0.66%0.23%
Return on Equity (TTM) i-2.21%0.10%
Debt to Equity (MRQ) i-4.0152.37
Cash & Liquidity
Book Value per Share (MRQ)$-0.56$4.99
Cash per Share (MRQ)$1.10$0.15
Operating Cash Flow (TTM) i$347.37M$3.56B
Levered Free Cash Flow (TTM) i$256.42M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: BioCryst Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricBCRX (Apr 24, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i7.0918.72
Forward P/E i10.7015.42
PEG Ratio i-0.0115.42
Price to Sales (TTM) i2.463.78
Price to Book (MRQ) i-15.531.88
Market Capitalization
Market Capitalization i$2.20B$42.40B
Enterprise Value i$2.35B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i2.698.23
Enterprise to EBITDA i6.7133.08
Risk & Other Metrics
Beta i0.690.33
Book Value per Share (MRQ) i$-0.56$4.99

Financial Statements Comparison: BioCryst Pharmaceuticals Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBCRX (2025)HLN (2025)
Revenue/Sales i874.84M11.03B
Cost of Goods Sold i19.08M3.95B
COGS % of Revenue i2.2%35.8%
Gross Profit i855.76M7.08B
Gross Margin i97.8%64.2%
Research & Development i166.13M316.00M
Operating Income (EBIT) i340.99M2.41B
Operating Margin i39.0%21.9%
EBITDA i365.14M2.81B
EBITDA Margin i41.7%25.5%
Pre-Tax Income i267.39M2.15B
Pre-Tax Income % of Revenue i30.6%19.5%
Income Tax i3.53M472.00M
Income Tax % of Revenue i0.4%4.3%
Net Income (Profit) i263.86M1.68B
Profit Margin i30.2%15.2%

Balance Sheet & Liquidity Metrics

MetricBCRX (2025)HLN (2025)
Cash & Equivalents i89.74M1.26B
Total Current Assets i404.35M4.55B
Total Current Assets % of Revenue i46.2%41.3%
Total Current Liabilities i196.07M4.93B
Total Current Liabilities % of Revenue i22.4%44.7%
Long-Term Debt i437.25M7.75B
Long-Term Debt % of Revenue i50.0%70.2%
Total Shareholders Equity i-119.15M16.48B
Retained Earnings i-1.51B27.85B
Retained Earnings % of Revenue i-172.2%252.5%
Property, Plant & Equipment i15.80M1.00M

Cash Flow Statement Comparison

MetricBCRX (2025)HLN (2025)
Operating Cash Flow i327.78M2.19B
Operating Cash Flow % of Revenue i37.5%19.8%
Capital Expenditures i-2.47M-322.00M
Free Cash Flow i344.90M2.22B
FCF Margin i39.4%20.1%
Debt Repayment i-301.99M-1.35B
Common Stock Repurchase iN/A-654.00M

Short Interest & Institutional Ownership Analysis

MetricBCRXHLN
Shares Short i35.19M19.28M
Short Ratio i5.352.14
Short % of Float i14.08%0.43%
Shares Outstanding i213.06M8.91B
Float Shares i218.18M8.86B
% Held by Insiders i1.31%0.01%
% Held by Institutions i89.14%12.74%
% Held by Public i9.55%87.25%

Dividend Analysis & Yield Comparison: BioCryst Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricBCRXHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025